- Home
- PRPO vs MCRB Comparison
PRPO vs MCRB Comparison
Compare PRPO & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRPO | MCRB |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 47.4M |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PRPO | MCRB |
|---|---|---|
| Price | $29.44 | $5.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 97.5K | 58.5K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,049,000.00 | $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.77 | N/A |
| 52 Week Low | $14.28 | $4.32 |
| 52 Week High | $33.63 | $29.98 |
Technical Indicators
Market Signals| Indicator | PRPO | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 65.82 | 48.84 |
| Support Level | $21.45 | $4.59 |
| Resistance Level | $33.63 | $5.65 |
| Average True Range (ATR) | 2.14 | 0.26 |
| MACD | 0.53 | 0.10 |
| Stochastic Oscillator | 73.67 | 72.46 |
Price Performance
Historical ComparisonAbout PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.